Justin Bowers
Stock Analyst at Deutsche Bank
(2.46)
# 2,993
Out of 5,040 analysts
133
Total ratings
47.7%
Success rate
1.2%
Average return
Main Sectors:
Stocks Rated by Justin Bowers
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ATR AptarGroup | Initiated Coverage: Buy | $150 | $121.81 | +23.14% | 1 | Oct 7, 2026 | |
| STVN Stevanato Group | Initiated Coverage: Hold | $22 | $19.21 | +14.52% | 1 | Oct 7, 2026 | |
| CRL Charles River Laboratories International | Rated: Buy | $300 → $320 | $298.00 | +7.38% | 13 | Sep 25, 2026 | |
| TMO Thermo Fisher Scientific | Reiterated: Buy | $630 → $720 | $651.98 | +10.43% | 11 | Sep 25, 2026 | |
| CON Concentra Group Holdings Parent | Rated: Buy | $32 → $41 | $36.61 | +11.99% | 3 | Aug 10, 2026 | |
| WAT Waters | Rated: Hold | $350 → $400 | $429.13 | -6.79% | 11 | Aug 5, 2026 | |
| AVTR Avantor | Reiterated: Hold | $25 → $13 | $15.39 | -15.53% | 7 | Jul 30, 2026 | |
| FTRE Fortrea Holdings | Reiterated: Hold | $14 → $20 | $20.37 | -1.82% | 7 | Jul 30, 2026 | |
| MEDP Medpace Holdings | Reiterated: Hold | $430 → $535 | $602.70 | -11.23% | 4 | Jul 23, 2026 | |
| DHR Danaher | Rated: Buy | $270 → $240 | $217.46 | +10.37% | 11 | Jul 22, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $66 → $73 | $72.47 | +0.73% | 9 | Jun 26, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $370 → $188 | $164.50 | +14.29% | 8 | Jun 25, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $10 → $6 | $7.21 | -16.78% | 6 | May 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $17 → $23 | $77.28 | -70.24% | 9 | May 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $345 → $315 | $363.27 | -13.29% | 6 | Feb 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $260 → $220 | $258.88 | n/a | 16 | Jul 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $155 → $175 | $163.84 | n/a | 8 | Aug 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Hold | $70 | $122.54 | n/a | 1 | Sep 16, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $140 | $264.57 | n/a | 1 | Jan 17, 2014 |
AptarGroup
Oct 7, 2026
Initiated Coverage: Buy
Price Target: $150
Current: $121.81
Upside: +23.14%
Stevanato Group
Oct 7, 2026
Initiated Coverage: Hold
Price Target: $22
Current: $19.21
Upside: +14.52%
Charles River Laboratories International
Sep 25, 2026
Rated: Buy
Price Target: $300 → $320
Current: $298.00
Upside: +7.38%
Thermo Fisher Scientific
Sep 25, 2026
Reiterated: Buy
Price Target: $630 → $720
Current: $651.98
Upside: +10.43%
Concentra Group Holdings Parent
Aug 10, 2026
Rated: Buy
Price Target: $32 → $41
Current: $36.61
Upside: +11.99%
Waters
Aug 5, 2026
Rated: Hold
Price Target: $350 → $400
Current: $429.13
Upside: -6.79%
Avantor
Jul 30, 2026
Reiterated: Hold
Price Target: $25 → $13
Current: $15.39
Upside: -15.53%
Fortrea Holdings
Jul 30, 2026
Reiterated: Hold
Price Target: $14 → $20
Current: $20.37
Upside: -1.82%
Medpace Holdings
Jul 23, 2026
Reiterated: Hold
Price Target: $430 → $535
Current: $602.70
Upside: -11.23%
Danaher
Jul 22, 2026
Rated: Buy
Price Target: $270 → $240
Current: $217.46
Upside: +10.37%
Jun 26, 2026
Downgraded: Hold
Price Target: $66 → $73
Current: $72.47
Upside: +0.73%
Jun 25, 2026
Reiterated: Buy
Price Target: $370 → $188
Current: $164.50
Upside: +14.29%
May 8, 2026
Reiterated: Buy
Price Target: $10 → $6
Current: $7.21
Upside: -16.78%
May 8, 2026
Reiterated: Hold
Price Target: $17 → $23
Current: $77.28
Upside: -70.24%
Feb 13, 2026
Reiterated: Buy
Price Target: $345 → $315
Current: $363.27
Upside: -13.29%
Jul 29, 2025
Reiterated: Buy
Price Target: $260 → $220
Current: $258.88
Upside: n/a
Aug 16, 2024
Reiterated: Buy
Price Target: $155 → $175
Current: $163.84
Upside: n/a
Sep 16, 2019
Initiated Coverage: Hold
Price Target: $70
Current: $122.54
Upside: n/a
Jan 17, 2014
Reiterated: Buy
Price Target: $140
Current: $264.57
Upside: n/a